Quality of Life

Weighing the Impact of Treatment Beyond the Disease

Patients reported having a quality of life similar to that at baseline throughout treatment1

This analysis is exploratory in nature and does not control for type 1 error; elements more distal to disease and treatment-related symptoms may be influenced by multiple non-drug factors.

More data: See FOSI Scale

For maintenance therapy after recurrent ovarian cancer, minimizing the impact of treatment on quality of life is a key consideration.

  • Patient-reported outcomes for quality of life were examined in the phase 3 NOVA trial using the FACT-Ovarian Symptom Index (FOSI)1,2
  • FOSI completion rates were high and similar in the 2 treatment groups: 75% to 97% in the ZEJULA group and 80% to 97% in the placebo group1
  • Patients were assessed at baseline, every 8 weeks for the first year, every 12 weeks thereafter during treatment, and then 6-10 weeks after treatment discontinuation3

 

References: 1. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164. 2. FOSI: for patients with ovarian cancer; a FACT-Ovarian Symptom Index (a subset of FACT-O containing 8 items). FACIT.org. http://www.facit.org/facitorg/questionnaires. Accessed November 18, 2017. 3. Data on file. TESARO, Inc. 

Efficacy summary

EFFICACY SUMMARY

See the clinical efficacy summary for ZEJULA

See Summary

Safety data

SAFETY DATA

Learn about the safety and tolerability of ZEJULA

See Safety

Starting ZEJULA

STARTING ZEJULA

When to start ZEJULA

See Recommendations

Dosing

DOSING

See recommendations for dose adjustment of ZEJULA

Review Dosing